REG - ReNeuron Group plc - Total Voting Rights

ReNeuronAnnouncement

01/07/2021 07:00

RNS Number : 7068D
  
ReNeuron Group plc
  
01 July 2021
  
 

 
ReNeuron Group plc
("ReNeuron" or the "Company")
 
Total Voting Rights
 
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that as at 30 June 2021, the Company had 56,936,402 ordinary shares in issue, each carrying one voting right. This follows the issue 72,697 new shares arising from the exercise of options by retired non-executive directors, such shares having been admitted under the Company's existing block listing arrangement. 
 
As the Company holds no ordinary shares in treasury, the figure of 56,936,402 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
  
ENDS
 
Contacts:
 




ReNeuron


www.reneuron.com/investors




Olav Hellebø, Chief Executive Officer 


Via Walbrook PR




 


 




Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
Ben Maddison, Stewart Wallace


+44 (0)20 7710 7600
 




 


 




Allenby Capital Limited (Joint Broker)
James Reeve/George Payne (Corporate Finance)
Tim Sohal (Sales & Corporate Broking)


+44 (0)20 3328 5656




  


 




Walbrook PR (Media & Investor Relations) 


+44 (0)20 7933 8780 or reneuron@walbrookpr.com




Paul McManus, Alice Woodings


+44 (0)7980 541 893 / +44 (0)7407 804 654




 
 
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments for disease with significant unmet needs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.
 
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders.  The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice; in-house programmes are currently focused on treatments for blood cancers and diabetes.
 
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
TVRMZGFVDGRGMZM